The APP Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited population of A-549 cells with targeted disruption of the amyloid precursor protein (APP) gene. This polyclonal knockout pool offers a heterogeneous loss-of-function model, circumventing clonal artifacts while ensuring robust target-gene ablation. The polyclonal format is particularly suited for studies requiring a broad representation of genetic backgrounds.
A-549 cells, derived from lung carcinoma tissue of a 58-year-old Caucasian male, serve as a well-characterized model of type II alveolar epithelial cells. Widely used in lung adenocarcinoma research, these adherent cells retain epithelial morphology and are amenable to genetic manipulation and functional assays, making them an ideal chassis for generating knockout models.
APP is a type I transmembrane protein proteolytically processed by BACE1 and the ??-secretase complex (PSEN1, NCSTN, APH1A, PSENEN) to yield amyloid-beta peptides and the AICD. AICD forms complexes with APBB1 and APBA1 and can translocate to the nucleus to influence gene expression. Through its interactions, APP modulates signaling pathways including Notch and Wnt. Upstream regulators such as reelin and F-spondin control APP processing, while downstream effectors encompass GSK3B and TP53. Additionally, APP interacts with KIF5B, linking it to intracellular trafficking and cell adhesion via integrin-mediated mechanisms.
Within A-549 lung adenocarcinoma cells, APP has been associated with cell adhesion, migration, and proliferation, potentially via integrin-mediated pathways. Disruption of APP in this context enables dissection of its role in tumorigenic processes and may reveal crosstalk between amyloidogenic processing and cancer-signaling networks. Because A-549 cells express the necessary secretases, this knockout model also permits investigation of ??-secretase activity and amyloid-beta production in a non-neuronal background.
Typical applications include western blotting, RT-qPCR, and amyloid-beta ELISA for expression and secretome analysis, as well as wound healing and MTT assays for phenotypic assessment of migration and viability. Co-immunoprecipitation can probe interactions with BACE1, PSEN1, and APBB1, while immunofluorescence microscopy visualizes subcellular localization changes. The polyclonal nature supports population-level analyses in drug library screens targeting Alzheimer??s disease and lung cancer. For further details, please contact Ascent Research.
